Atlas Trials

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

Clinical trial NCT05572515 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05572515
Sponsor
Janssen Research & Development, LLC
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 3
Study type
INTERVENTIONAL
Relapsed or Refractory Multiple Myeloma
Start date
2023-03-29
Primary completion
2025-10-13
Enrollment
614

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.